RapidAccess.ai published clinical case recommendations for tirzepatide in chronic weight management, including a reimbursement request for a restricted population of BMI ≥ 27 with prediabetes.
Published
Signal category
Research & Knowledge
Quote
“In chronic weight management (Zepbound, SR0920-000), Tirzepatide’s reimbursement was sought in a more restricted population.”
— RapidAccess.ai team
Company
RapidAccess.ai
Flexible Analytics for Pricing & Reimbursement
- Industry
- Pharmaceutical Manufacturing
- Company size
- 4 employees
RAPID Access is an AI-powered market access intelligence platform designed for pharma and biotech teams that need faster, more precise, and more actionable insight across the payer landscape. By consolidating key reimbursement and access signals into a single platform, RAPID helps teams cut through fragmentation, reduce manual tracking, and move beyond static assumptions. The platform addresses persistent market access challenges, including manual monitoring of CDA-AMC and pCPA activity, time-intensive review of reimbursement reports, ongoing competitive intelligence needs, and the difficulty of refining strategy as new analogues or evidence emerge. RAPID offers live views of submission and agency trends, structured file briefs for efficient review, customizable performance analyses by indication and asset, and flexible analytics that help teams test assumptions and identify relevant comparators with speed. Ultimately, RAPID enables teams to spend less time on administrative work and more time on strategy, explore trends across 60+ parameters, and generate rapid, tailored answers to complex market access questions.
Founded 2025